Elizabeth Kieras

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

Seth Forman, David M. Pariser, Yves Poulin et al. · Journal of Investigative Dermatology · 2020 · 105 citations

Medicine, Pharmacology, Pharmacotherapy +14

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis

Christopher Banfield, Matthew Scaramozza, Weidong Zhang et al. · The Journal of Clinical Pharmacology · 2017 · 94 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study

G Schmieder, Zoé Kececioglu Draelos, David M. Pariser et al. · British Journal of Dermatology · 2017 · 93 citations

Medicine, Pharmacology, Pharmacotherapy +11

Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis

Karen Page, Mayte Suárez‐Fariñas, Maria Suprun et al. · Journal of Investigative Dermatology · 2020 · 56 citations · Full text

Medicine, Dermatology, Pharmacology +17

Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study

Elena Peeva, Martin R. Hodge, Elizabeth Kieras et al. · British Journal of Clinical Pharmacology · 2018 · 46 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12